Skip to main content
Top
Published in: Clinical Rheumatology 9/2016

01-09-2016 | Original Article

Relationship of serum osteoprotegerin with arterial stiffness, preclinical atherosclerosis, and disease activity in patients with ankylosing spondylitis

Authors: Münevver Serdaroğlu Beyazal, Turan Erdoğan, Aysegül Kücükali Türkyılmaz, Gül Devrimsel, Medine Cumhur Cüre, Mehmet Beyazal, Ismail Sahin

Published in: Clinical Rheumatology | Issue 9/2016

Login to get access

Abstract

Patients with ankylosing spondylitis (AS) reportedly have a higher mortality and morbidity risk. Osteoprotegerin (OPG) was recently defined as an important cardiovascular (CV) marker in the general population. We aimed to assess the relationship of serum OPG levels with arterial stiffness, carotid intima media thickness (CIMT), and clinical and laboratory data in AS patients. We examined 60 AS patients without CV disease or risk factors and 50 healthy controls. Disease activity was evaluated using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS), whereas functional capacity was evaluated using the Bath Ankylosing Spondylitis Functional Index (BASFI). Serum OPG levels were measured with the enzyme-linked immunosorbent assay. Carotid-femoral pulse wave velocity (PWV) was used as an indicator of arterial stiffness, whereas CIMT (examined via carotid ultrasonography) was used to evaluate preclinical atherosclerosis. The mean serum OPG level, PWV, and CIMT were significantly higher in AS patients than in controls (106.7 ± 50.9 vs. 58.1 ± 12.7 pg/mL; 7.4 ± 1.8 vs. 6.2 ± 1.2 m/s; 0.72 ± 0.13 vs. 0.57 ± 0.07 mm, respectively; P < 0.001 for all). In AS patients, the serum OPG levels were not significantly correlated with PWV and CIMT but were significantly correlated with erthrocyte sedimentation rate, BASFI, and ASDAS. AS patients without CV disease or risk exhibited high OPG levels and increased PWV and CIMT values. Although OPG levels were not significantly correlated with PWV or CIMT, future long-term follow-up studies will help define the predictive value of OPG in these patients.
Literature
1.
go back to reference Choe JY, Lee MY, Rheem I, Rhee MY, Park SH, Kim SK (2008) No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 75:548–553CrossRefPubMed Choe JY, Lee MY, Rheem I, Rhee MY, Park SH, Kim SK (2008) No differences of carotid intima-media thickness between young patients with ankylosing spondylitis and healthy controls. Joint Bone Spine 75:548–553CrossRefPubMed
2.
go back to reference Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69(2):325–331CrossRefPubMed Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK et al (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69(2):325–331CrossRefPubMed
3.
go back to reference John H, Kitas G (2012) Inflammatory arthritis as a novel risk factor for cardiovascular disease. Eur J Int Med 23:575–579CrossRef John H, Kitas G (2012) Inflammatory arthritis as a novel risk factor for cardiovascular disease. Eur J Int Med 23:575–579CrossRef
4.
go back to reference Tyrrell PN, Beyene J, Feldman BM, McCrindle BW, Silverman ED, Bradley TJ (2010) Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 30(5):1014–1026CrossRefPubMed Tyrrell PN, Beyene J, Feldman BM, McCrindle BW, Silverman ED, Bradley TJ (2010) Rheumatic disease and carotid intima-media thickness: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 30(5):1014–1026CrossRefPubMed
5.
go back to reference Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Martin J, Llorca J (2008) Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum 38(2):67–70CrossRefPubMed Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Martin J, Llorca J (2008) Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum 38(2):67–70CrossRefPubMed
6.
go back to reference O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr (1999) Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Colloborative Research Group. N Engl J Med 340:14–22CrossRefPubMed O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr (1999) Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Colloborative Research Group. N Engl J Med 340:14–22CrossRefPubMed
7.
go back to reference Mathieu S, Joly H, Baron G, Tournadre A, Dubost JJ, Ristori JM, Lusson JR, Soubrier M (2008) Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology 47:1203–1207CrossRefPubMed Mathieu S, Joly H, Baron G, Tournadre A, Dubost JJ, Ristori JM, Lusson JR, Soubrier M (2008) Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology 47:1203–1207CrossRefPubMed
8.
go back to reference Venuraju SM, Yerramasu A, Corder R, Lahiri A (2010) Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 55(19):2049–2061CrossRefPubMed Venuraju SM, Yerramasu A, Corder R, Lahiri A (2010) Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 55(19):2049–2061CrossRefPubMed
9.
go back to reference Van Campenhout A, Golledge J (2009) Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 204(2):321–329CrossRefPubMed Van Campenhout A, Golledge J (2009) Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 204(2):321–329CrossRefPubMed
10.
go back to reference Asanuma YF, Shimada Y, Kouzu N, Yokota K, Nakajima K, Sato K, Akiyama Y, Isozaki M, Mikami AS, Kobayashi H, Mimura T (2013) Serum osteoprotegerin concentration is associated with carotid atherosclerotic plaque in patients with rheumatoid arthritis. Mod Rheumatol 23(2):269–275CrossRefPubMed Asanuma YF, Shimada Y, Kouzu N, Yokota K, Nakajima K, Sato K, Akiyama Y, Isozaki M, Mikami AS, Kobayashi H, Mimura T (2013) Serum osteoprotegerin concentration is associated with carotid atherosclerotic plaque in patients with rheumatoid arthritis. Mod Rheumatol 23(2):269–275CrossRefPubMed
11.
go back to reference Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:490–495CrossRefPubMed Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:490–495CrossRefPubMed
12.
go back to reference Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y (2002) Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106:1192–1194CrossRefPubMed Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y (2002) Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106:1192–1194CrossRefPubMed
13.
go back to reference Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC (2003) Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88:1024–1028CrossRefPubMed Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC (2003) Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88:1024–1028CrossRefPubMed
14.
go back to reference Rhee EJ, Lee WY, Kim SY, Kim BJ, Sung KC, Kim BS, Kang JH, Oh KW, Oh ES, Baek KH, Kang MI, Woo HY, Park HS, Kim SW, Lee MH, Park JR (2005) Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci 108:237–243, LondCrossRefPubMed Rhee EJ, Lee WY, Kim SY, Kim BJ, Sung KC, Kim BS, Kang JH, Oh KW, Oh ES, Baek KH, Kang MI, Woo HY, Park HS, Kim SW, Lee MH, Park JR (2005) Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci 108:237–243, LondCrossRefPubMed
15.
go back to reference Hosbond SE, Poulsen TS, Diederichsen AC, Nybo M, Rasmussen LM, Mickley H (2012) Osteoprotegerin as a marker of atherosclerosis: a systematic update. Scand Cardiovasc J 46(4):203–211CrossRefPubMed Hosbond SE, Poulsen TS, Diederichsen AC, Nybo M, Rasmussen LM, Mickley H (2012) Osteoprotegerin as a marker of atherosclerosis: a systematic update. Scand Cardiovasc J 46(4):203–211CrossRefPubMed
16.
go back to reference Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368CrossRefPubMed Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368CrossRefPubMed
17.
go back to reference Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed
18.
go back to reference Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70:47–53CrossRefPubMed Machado P, Landewé R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70:47–53CrossRefPubMed
19.
go back to reference Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed
20.
go back to reference Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G (2006) The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 4(6):801–811CrossRefPubMed Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G (2006) The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 4(6):801–811CrossRefPubMed
21.
go back to reference Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W, Spitzauer S, Grampp S, Kainberger F, Ebner W, Smolen JS, Pietschmann P (2002) Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 29:1430–1436PubMed Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W, Spitzauer S, Grampp S, Kainberger F, Ebner W, Smolen JS, Pietschmann P (2002) Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 29:1430–1436PubMed
22.
go back to reference Chen CH, Chen HA, Liao HT, Liu CH, Tsai CY, Chou CT (2010) Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation. Clin Rheumatol 29(10):1155–1161CrossRefPubMed Chen CH, Chen HA, Liao HT, Liu CH, Tsai CY, Chou CT (2010) Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation. Clin Rheumatol 29(10):1155–1161CrossRefPubMed
23.
go back to reference Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY, Kim HA, Choi HJ, Park W (2012) Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int 32(8):2523–2527CrossRefPubMed Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY, Kim HA, Choi HJ, Park W (2012) Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int 32(8):2523–2527CrossRefPubMed
24.
go back to reference Sveaas SH, Berg IJ, Provan SA, Semb AG, Olsen IC, Ueland T, Aukrust P, Vøllestad N, Hagen KB, Kvien TK, Dagfinrud H (2015) Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative study. Scand J Rheumatol 44(2):118–124CrossRefPubMed Sveaas SH, Berg IJ, Provan SA, Semb AG, Olsen IC, Ueland T, Aukrust P, Vøllestad N, Hagen KB, Kvien TK, Dagfinrud H (2015) Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: a cross-sectional comparative study. Scand J Rheumatol 44(2):118–124CrossRefPubMed
25.
go back to reference Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J (2004) Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109(18):2175–2180CrossRefPubMed Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J (2004) Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109(18):2175–2180CrossRefPubMed
26.
go back to reference Genre F, López-Mejías R, Miranda-Filloy JA, Ubilla B, Carnero-López B, Palmou-Fontana N, Gómez-Acebo I, Blanco R, Rueda-Gotor J, Pina T, González-Juanatey C, Llorca J, González-Gay MÁ (2014) Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheumatol 32(5):640–646PubMed Genre F, López-Mejías R, Miranda-Filloy JA, Ubilla B, Carnero-López B, Palmou-Fontana N, Gómez-Acebo I, Blanco R, Rueda-Gotor J, Pina T, González-Juanatey C, Llorca J, González-Gay MÁ (2014) Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheumatol 32(5):640–646PubMed
27.
go back to reference Asanuma Y, Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, Raggi P, Sokka T, Pincus T, Stein CM (2007) Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis 135–41 Asanuma Y, Chung CP, Oeser A, Solus JF, Avalos I, Gebretsadik T, Shintani A, Raggi P, Sokka T, Pincus T, Stein CM (2007) Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis 135–41
28.
go back to reference Dessein PH, López-Mejias R, González-Juanatey C, Genre F, Miranda-Filloy JA, Llorca J, González-Gay MA (2014) Independent relationship of osteoprotegerin concentrations with endothelial activation and carotid atherosclerosis in patients with severe rheumatoid arthritis. J Rheumatol 41(3):429–436CrossRefPubMed Dessein PH, López-Mejias R, González-Juanatey C, Genre F, Miranda-Filloy JA, Llorca J, González-Gay MA (2014) Independent relationship of osteoprotegerin concentrations with endothelial activation and carotid atherosclerosis in patients with severe rheumatoid arthritis. J Rheumatol 41(3):429–436CrossRefPubMed
29.
go back to reference Nurhamed MT, van der Horst-Bruinsma, Maksymowych WP (2012) Cardiovascular and cerebrovascular diseases in ankylosing spondylitis: current insights. Curr Rheumatol Rep 14:415–421CrossRef Nurhamed MT, van der Horst-Bruinsma, Maksymowych WP (2012) Cardiovascular and cerebrovascular diseases in ankylosing spondylitis: current insights. Curr Rheumatol Rep 14:415–421CrossRef
30.
go back to reference Peters MJ, van Eijk IC, Smulders YM, Serne E, Dijkmans BA, van der Horst-Bruinsma IE, Nurmohamed MT (2010) Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 37(1):161–166CrossRefPubMed Peters MJ, van Eijk IC, Smulders YM, Serne E, Dijkmans BA, van der Horst-Bruinsma IE, Nurmohamed MT (2010) Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 37(1):161–166CrossRefPubMed
31.
go back to reference Bodnár N, Kerekes G, Seres I, Paragh G, Kappelmayer J, Némethné ZG, Szegedi G, Shoenfeld Y, Sipka S, Soltész P, Szekanecz Z, Szántó S (2011) Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol 38(4):723–729CrossRefPubMed Bodnár N, Kerekes G, Seres I, Paragh G, Kappelmayer J, Némethné ZG, Szegedi G, Shoenfeld Y, Sipka S, Soltész P, Szekanecz Z, Szántó S (2011) Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol 38(4):723–729CrossRefPubMed
32.
go back to reference Hamdi W, Chelli Bouaziz M, Zouch I, Ghannouchi MM, Haouel M, Ladeb MF, Kchir MM (2012) Assessment of preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 39(2):322–326CrossRefPubMed Hamdi W, Chelli Bouaziz M, Zouch I, Ghannouchi MM, Haouel M, Ladeb MF, Kchir MM (2012) Assessment of preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol 39(2):322–326CrossRefPubMed
33.
go back to reference Chen Y, Chung HY, Zhao CT, Wong A, Zhen Z, Tsang HH, Lau CS, Tse HF, Yiu KH (2015) Left ventricular myocardial dysfunction and premature atherosclerosis in patients with axial spondyloarthritis. Rheumatology (Oxford) 54(2):292–301CrossRef Chen Y, Chung HY, Zhao CT, Wong A, Zhen Z, Tsang HH, Lau CS, Tse HF, Yiu KH (2015) Left ventricular myocardial dysfunction and premature atherosclerosis in patients with axial spondyloarthritis. Rheumatology (Oxford) 54(2):292–301CrossRef
34.
go back to reference Gonzalez-Jaunatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Dierssen T, Vaqueiro I, Blanco R, Martin J, Llorca J, Gonzalaez-Gay MA (2009) The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 88(6):358–365CrossRef Gonzalez-Jaunatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Dierssen T, Vaqueiro I, Blanco R, Martin J, Llorca J, Gonzalaez-Gay MA (2009) The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 88(6):358–365CrossRef
35.
go back to reference Berg IJ, Semb AG, van der Heijde D, Kvien TK, Olsen IC, Dagfinrud H, Provan SA (2015) CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: results after 5-year follow-up. Ann Rheum Dis 74(8):1562–1566CrossRefPubMed Berg IJ, Semb AG, van der Heijde D, Kvien TK, Olsen IC, Dagfinrud H, Provan SA (2015) CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: results after 5-year follow-up. Ann Rheum Dis 74(8):1562–1566CrossRefPubMed
36.
go back to reference Jain S, Khera R, Corrales-Medina VF, Townsend RR, Chirinos JA (2014) Inflammation and arterial stiffness in humans. Atherosclerosis 237(2):381–390CrossRefPubMed Jain S, Khera R, Corrales-Medina VF, Townsend RR, Chirinos JA (2014) Inflammation and arterial stiffness in humans. Atherosclerosis 237(2):381–390CrossRefPubMed
37.
go back to reference Capkın E, Kiriş A, Karkucak M, Durmuş I, Gökmen F, Cansu A, Tosun M, Ayar A (2011) Investigation of effects of different treatment modalities on structural and functional vessel wall properties in patients with ankylosing spondylitis. Joint Bone Spine 78:378–382CrossRefPubMed Capkın E, Kiriş A, Karkucak M, Durmuş I, Gökmen F, Cansu A, Tosun M, Ayar A (2011) Investigation of effects of different treatment modalities on structural and functional vessel wall properties in patients with ankylosing spondylitis. Joint Bone Spine 78:378–382CrossRefPubMed
38.
go back to reference Berg IJ, van der Heijde D, Dagfinrud H, Seljeflot I, Olsen IC, Kvien TK, Semb AG, Provan SA (2015) Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: a cross-sectional study. J Rheumatol 42(4):645–653CrossRefPubMed Berg IJ, van der Heijde D, Dagfinrud H, Seljeflot I, Olsen IC, Kvien TK, Semb AG, Provan SA (2015) Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: a cross-sectional study. J Rheumatol 42(4):645–653CrossRefPubMed
39.
go back to reference Capkın E, Karkucak M, Kiriş A, Durmuş I, Karaman K, Karaca A, Tosun M, Ayar A (2012) Anti-TNF-α therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up. Rheumatology 51:910–914CrossRefPubMed Capkın E, Karkucak M, Kiriş A, Durmuş I, Karaman K, Karaca A, Tosun M, Ayar A (2012) Anti-TNF-α therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up. Rheumatology 51:910–914CrossRefPubMed
40.
go back to reference Mathieu S, Pereira B, Couderc M, Rabois E, Dubost JJ, Soubrier M (2013) No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months. Rheumatology 52:204–209CrossRefPubMed Mathieu S, Pereira B, Couderc M, Rabois E, Dubost JJ, Soubrier M (2013) No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months. Rheumatology 52:204–209CrossRefPubMed
41.
go back to reference Angel K, Provan A, Gulseth HL, Mowinckel P, Kristian TK, Atar D (2010) Tumor Necrosis factor-α antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 55:333–338CrossRefPubMed Angel K, Provan A, Gulseth HL, Mowinckel P, Kristian TK, Atar D (2010) Tumor Necrosis factor-α antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension 55:333–338CrossRefPubMed
42.
go back to reference Taylan A, Sari I, Akinci B, Bilge S, Kozaci D, Akar S, Colak A, Yalcin H, Gunay N, Akkoc N (2012) Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord 13:191CrossRefPubMedPubMedCentral Taylan A, Sari I, Akinci B, Bilge S, Kozaci D, Akar S, Colak A, Yalcin H, Gunay N, Akkoc N (2012) Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord 13:191CrossRefPubMedPubMedCentral
Metadata
Title
Relationship of serum osteoprotegerin with arterial stiffness, preclinical atherosclerosis, and disease activity in patients with ankylosing spondylitis
Authors
Münevver Serdaroğlu Beyazal
Turan Erdoğan
Aysegül Kücükali Türkyılmaz
Gül Devrimsel
Medine Cumhur Cüre
Mehmet Beyazal
Ismail Sahin
Publication date
01-09-2016
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 9/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3198-9

Other articles of this Issue 9/2016

Clinical Rheumatology 9/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.